US · OGN
Organon & Co.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Jersey City, NJ 07302
- Website
- organon.com
Price · as of 2025-12-31
$13.29
Market cap 1.9B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $47.55 | +257.79% |
| Intrinsic Value(DCF) | $3.82 | -71.26% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $3.79 | -71.47% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $73.17 | $0.00 | |||
| 2020 | $46.08 | $0.00 | |||
| 2021 | $29.98 | $92.17 | $0.60 | $0.00 | $25.99 |
| 2022 | $19.74 | $63.84 | $1.11 | $0.00 | $22.44 |
| 2023 | $17.15 | $51.98 | $0.52 | $0.00 | $37.95 |
| 2024 | $15.29 | $50.86 | $3.49 | $0.00 | $34.40 |
| 2025 | $7.19 | $47.55 | $2.21 | $0.00 | $3.79 |
AI valuation
Our deep-learning model estimates Organon & Co.'s (OGN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $47.55
- Current price
- $13.29
- AI upside
- +257.79%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.82
-71.26% upside
Graham-Dodd
—
— upside
Graham Formula
$3.79
-71.47% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OGN | Organon & Co. | $13.29 | 1.9B | +258% | -71% | — | -71% | 9.98 | 2.48 | 0.30 | 7.87 | — | -0.41 | 54.09% | 20.67% | 3.01% | 30.56% | 6.35% | 1.44% | 11.70 | 2.55 | 1.82 | 0.84 | 6.41 | -7838.00% | -292.00% | -850.00% | 28.84% | 0.29 | 6.04% | 4.72% | 47.10% | 11.95% | 7.85 | 18.76 | 1.62 | 1.09 |
| ALVO | Alvotech | $3.99 | 1.24B | +1,454% | +12% | — | — | -12.88 | -7.24 | 6.10 | -127.84 | — | -6.72 | 62.16% | 14.22% | -47.35% | 34.47% | 16.24% | -21.36% | -2.88 | 0.44 | 2.35 | 1.57 | -35.28 | -6420.00% | 43556.00% | -1807.00% | -9.84% | -1.22 | -68.51% | 0.00% | 0.00% | 0.00% | 59.25 | -14.04 | 8.43 | -0.85 |
| AUPH | Aurinia Pharmaceuticals I… | $14.17 | 1.87B | +206% | +451% | +6% | +317% | 6.65 | 3.28 | 6.75 | 12.42 | 0.13 | 3.31 | 88.46% | 37.06% | 101.47% | 59.91% | 58.85% | 44.11% | 0.13 | 24.23 | 5.25 | 4.69 | -0.04 | 516718.00% | 2038.00% | 20699.00% | 7.09% | 1.45 | 75.96% | 0.00% | 0.00% | 5.21% | 15.12 | 11.71 | 5.60 | 6.99 |
| AVDL | Avadel Pharmaceuticals pl… | $21.64 | 2.12B | +273% | +125% | — | — | -15.41 | 10.19 | 4.45 | -19.13 | — | 13.20 | 90.97% | -25.07% | -28.87% | -60.44% | -426.40% | -29.69% | 0.02 | -3.91 | 2.75 | 2.21 | 1.40 | -7450.00% | 50479.00% | -6350.00% | -6.23% | -0.96 | -474.12% | 0.00% | 0.00% | 7.16% | -16.05 | -14.51 | 4.02 | -0.97 |
| GRDN | Guardian Pharmacy Service… | $33.51 | 2.12B | -11% | +240% | — | — | -16.12 | 8.03 | 0.93 | -27.12 | — | 19.59 | 19.89% | -5.12% | -7.11% | -83.14% | -46.27% | -24.00% | 0.26 | -19.19 | 1.05 | 0.71 | -0.75 | -55385.00% | 1742.00% | -2608.00% | 3.63% | 0.40 | 30.59% | 3.12% | -50.30% | 11.06% | -18.72 | 28.32 | 0.96 | 7.31 |
| HRMY | Harmony Biosciences Holdi… | $28.54 | 1.64B | +155% | +609% | +1% | +178% | — | 1.91 | 1.91 | 4.41 | — | 2.13 | 77.16% | 24.00% | 18.27% | 0.00% | 43.46% | 0.00% | 0.28 | 14.23 | 3.60 | 3.46 | -2.01 | 797.00% | 2151.00% | 5909.00% | 20.94% | 1.38 | 98.30% | 0.00% | — | 14.52% | 5.40 | 3.24 | 1.30 | 4.50 |
| MD | Pediatrix Medical Group, … | $19.85 | 1.7B | +94% | -35% | -74% | -67% | — | 1.93 | 0.87 | 6.67 | — | -4.05 | 24.66% | 12.07% | 8.64% | 0.00% | 16.78% | 0.00% | 0.76 | 6.43 | 1.66 | 1.62 | 1.04 | -26303.00% | -492.00% | 3689.00% | 15.14% | 0.59 | 24.00% | 0.00% | — | 14.02% | 7.92 | 7.24 | 0.96 | 2.03 |
| NUVB | Nuvation Bio Inc. | $5.91 | 2.02B | — | — | — | — | -0.96 | 1.17 | 68.96 | -0.09 | -0.19 | 1.18 | 10.10% | -7527.33% | -7213.76% | -106.27% | 3695.49% | -97.74% | 0.02 | -1737.91 | 9.04 | 8.91 | 0.05 | 50286.00% | — | 9183.00% | -24.05% | -2.24 | 814.24% | 0.00% | 0.00% | 0.00% | -0.08 | -0.38 | 6.24 | -0.68 |
| PAHC | Phibro Animal Health Corp… | $54.59 | 2.21B | +18% | +113% | -92% | -25% | 32.91 | 5.56 | 1.23 | 15.48 | 1.75 | 8.38 | 30.85% | 8.52% | 3.72% | 17.80% | 9.58% | 4.12% | 2.67 | 3.32 | 2.76 | 1.04 | 4.72 | 188333.00% | 2737.00% | -976.00% | 2.63% | 0.27 | 5.11% | 1.22% | 40.30% | 1.22% | 20.57 | 54.33 | 1.75 | 2.84 |
| SEM | Select Medical Holdings C… | $14.97 | 1.86B | +47% | -60% | — | +4% | 12.67 | 1.09 | 0.34 | 10.42 | — | -2.45 | 11.54% | 6.14% | 2.68% | 8.63% | 5.42% | 2.55% | 2.17 | 2.85 | 1.04 | 0.90 | 6.93 | -2892.00% | 512.00% | -2908.00% | 20.66% | 0.35 | 7.88% | 1.70% | 21.50% | 7.10% | 16.53 | 14.45 | 1.01 | 1.62 |
| TLRY | Tilray Brands, Inc. | $7.87 | 796.82M | -67% | -67% | — | — | -0.19 | 0.28 | 0.51 | -0.23 | -0.03 | 0.57 | 29.29% | -277.93% | -266.25% | -88.71% | -84.34% | -68.11% | 0.22 | -55.23 | 2.46 | 1.35 | -0.05 | 65170.00% | 484.00% | 11348.00% | -30.24% | -0.34 | -4.97% | 0.00% | 0.00% | 12.04% | -0.22 | -3.87 | 0.60 | -5.74 |
About Organon & Co.
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
- CEO
- Joseph T. Morrissey Jr.
- Employees
- 10K
- Beta
- 0.55
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.82 ÷ $13.29) − 1 = -71.26% (DCF, example).